Volume 2, Issue 8
Editorialp. 755-757
Recombinant von Willebrand factor: is this the answer for treatment of von Willebrand disease? ***Recombinant VWF treatment
Author(s): Steve Keeney
Editorialp. 759-760
Primary sclerosing cholangitis clinical trials: mission impossible.... for now
Author(s): Bret Lashner
News and Viewsp. 761–763
Investigation into the assessment of tobacco use in clinical trials
Conference Reportp. 765-767
World Vaccine Trials Congress 2012
Author(s): Jonathan K Fallon,James L Gulley
Clinical Trail Methodologyp. 769-780
Approaches to the design of clinical trials for primary sclerosing cholangitis*** Design of clinical trials for primary sclerosing cholangitis
Author(s): Mohamad H Imam, Keith D Lindor, Jayant A Talwalkar
Review: Clinical Trail Outcomesp. 781-795
New developments in the diagnosis and treatment of von Willebrand disease
Author(s): Emmanuel J Favaloro
Review: Clinical Trail Outcomesp. 797-802
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
Author(s): BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomesp. 803-817
Prosthetic valve endocarditis: state of the heart ***Management of prosthetic valve endocarditis
Author(s): Avish Nagpal, Muhammad R Sohail ,James M Steckleberg
Review: Clinical Trail Outcomesp. 819-824
Clinical and experimental data on the use of laquinimod for the treatment of multiple sclerosis
Author(s): De-Hyung Lee, Ralf A Linker
Review: Clinical Trail Outcomesp. 825-833
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Author(s): Adrian Wagg
Review: Clinical Trail Outcomesp. 835-852
New developments in the treatment of ALK-driven malignancies
Author(s): Luca Mologni & Carlo Gambacorti-Passerini
